Non-invasive imaging reveals conditions that impact distribution and persistence of cells after in vivo administration

Scarfe, Lauren, Taylor, Arthur, Sharkey, Jack, Harwood, Rachel, Barrow, Michael, Comenge, Joan, Beeken, Lydia, Astley, Cai, Santeramo, Ilaria, Hutchinson, Claire
et al (show 10 more authors) Non-invasive imaging reveals conditions that impact distribution and persistence of cells after in vivo administration.

Access the full-text of this item by clicking on the Open Access link.


<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Cell-based regenerative medicine therapies are now frequently tested in clinical trials. In many conditions, cell therapies are administered systemically, but there is little understanding of their fate, and adverse events are often under-reported. Currently, it is only possible to assess safety and fate of cell therapies in preclinical studies, specifically by monitoring animals longitudinally using multimodal imaging approaches. Here, using a suite of <jats:italic>in vivo</jats:italic> imaging modalities to explore the fate of a range of human and murine cells, we investigate how route of administration, cell type and host immune status affect the fate of administered cells.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We applied a unique imaging toolkit combining bioluminescence, optoacoustic and magnetic resonance imaging modalities to assess the safety of different human and murine cell types by following their biodistribution and persistence in mice following administration into the venous or arterial system. <jats:bold>Results:</jats:bold> Longitudinal imaging analyses (i) suggested that the intra-arterial route may be more hazardous than intravenous administration for certain cell types; (ii) revealed that the potential of a mouse mesenchymal stem/stromal cell (MSC) line to form tumours, depended on administration route and mouse strain; and (iii) indicated that clinically tested human umbilical cord (hUC)-derived MSCs can transiently and unexpectedly proliferate when administered intravenously to mice.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In order to perform an adequate safety assessment of potential cell-based therapies, a thorough understanding of cell biodistribution and fate post administration is required. The non-invasive imaging toolbox used here can expose not only the general organ distribution of these therapies, but also a detailed view of their presence within different organs and, importantly, tumourigenic potential. Our observation that the hUC-MSCs but not the human bone marrow (hBM)-derived MSCs persisted for a period in some animals, suggests that therapies with these cells should proceed with caution.</jats:p></jats:sec>

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 18 Nov 2019 09:15
Last Modified: 19 Jan 2023 00:20
DOI: 10.1101/202101
Open Access URL: